Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection.
SARS-CoV-2
immunization
infectious disease
monoclonal antibodies
neutralizing antibodies
Journal
mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231
Informations de publication
Date de publication:
25 Sep 2023
25 Sep 2023
Historique:
medline:
25
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
aheadofprint
Résumé
Despite the success of COVID-19 vaccines in preventing infection and/or severe disease, there has been an increase in SARS-CoV-2 infections in vaccinated individuals owing to the waning vaccine-derived immunity, and the emergence of new variants which encode escape mutations in Spike. Following breakthrough infection in vaccinated individuals, an increase in neutralization breadth has been observed in sera/plasma. However, how exposure to a heterologous Spike broadens the neutralizing response at the monoclonal antibody (mAb) level is not fully understood. Through isolation of 119 mAbs from three individuals receiving two doses of BNT162b2 vaccine before becoming Delta or Omicron/BA.1 infected, we show that serum breadth occurs due to the presence of somatically mutated mAbs with broad neutralization activity indicative of re-activation and maturation of B cells generated through previous COVID-19 vaccination. Isolated mAbs frequently show reduced neutralization of current circulating variants including BA.2.75.2, XBB, XBB.1.5, and BQ.1.1 confirming continuous selective pressure on Spike to evolve and evade neutralization. However, isolation of mAbs that display effective cross-neutralization against all variants indicates the presence of conserved epitopes on the receptor binding domain and a lesser extent the N-terminal domain. These findings have implications for the selection of Spike antigens for next-generation COVID-19 vaccines. IMPORTANCE With the emergence of SARS-CoV-2 viral variants, there has been an increase in infections in vaccinated individuals. Here, we isolated monoclonal antibodies (mAbs) from individuals experiencing a breakthrough infection (Delta or BA.1) to determine how exposure to a heterologous Spike broadens the neutralizing antibody response at the monoclonal level. All mAbs isolated had reactivity to the Spike of the vaccine and infection variant. While many mAbs showed reduced neutralization of current circulating variants, we identified mAbs with broad and potent neutralization of BA.2.75.2, XBB, XBB.1.5, and BQ.1.1 indicating the presence of conserved epitopes on Spike. These results indicate that variant-based vaccine boosters have the potential to broaden the vaccine response.
Identifiants
pubmed: 37747187
doi: 10.1128/mbio.01206-23
pmc: PMC10653880
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0120623Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Références
Nat Microbiol. 2021 Nov;6(11):1433-1442
pubmed: 34654917
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
Immunity. 2021 Jun 8;54(6):1276-1289.e6
pubmed: 33836142
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Sci Immunol. 2022 Mar 18;7(69):eabm9060
pubmed: 35302862
Nat Rev Microbiol. 2023 Mar;21(3):162-177
pubmed: 36653446
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Nature. 2023 May;617(7961):592-598
pubmed: 37011668
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Cell Rep. 2022 May 3;39(5):110757
pubmed: 35477023
Nat Med. 2022 Mar;28(3):477-480
pubmed: 35046572
Nature. 2023 Feb;614(7948):521-529
pubmed: 36535326
Nature. 2022 Mar;603(7903):919-925
pubmed: 35090164
Immunity. 2022 Jun 14;55(6):998-1012.e8
pubmed: 35447092
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
N Engl J Med. 2023 Feb 9;388(6):565-567
pubmed: 36630611
Nature. 2022 Jul;607(7918):356-359
pubmed: 35523247
Cell Rep. 2022 Aug 23;40(8):111276
pubmed: 35981534
Lancet. 2021 Jul 31;398(10298):385-387
pubmed: 34274038
Proc Natl Acad Sci U S A. 2021 Jun 8;118(23):
pubmed: 34074774
Nature. 2009 Apr 2;458(7238):636-40
pubmed: 19287373
Cell. 2023 Jan 19;186(2):279-286.e8
pubmed: 36580913
Nature. 2021 Dec;600(7889):517-522
pubmed: 34619745
Cell Rep Med. 2022 Oct 18;3(10):100779
pubmed: 36208629
PLoS Pathog. 2022 Oct 3;18(10):e1010882
pubmed: 36191037
Nat Commun. 2023 Jan 4;14(1):53
pubmed: 36599850
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Ann Med Surg (Lond). 2022 Dec;84:104963
pubmed: 36415680
N Engl J Med. 2023 Feb 9;388(6):567-569
pubmed: 36630643
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
Nat Protoc. 2016 Oct;11(10):1908-1923
pubmed: 27658009
Cell Host Microbe. 2021 May 12;29(5):819-833.e7
pubmed: 33789084
Nat Immunol. 2023 Apr;24(4):690-699
pubmed: 36914890
Nat Immunol. 2017 Apr;18(4):456-463
pubmed: 28192417
Cell Host Microbe. 2022 Dec 14;30(12):1745-1758.e7
pubmed: 36356586
N Engl J Med. 2023 Jan 5;388(1):89-91
pubmed: 36476720
Nucleic Acids Res. 1999 Jan 1;27(1):209-12
pubmed: 9847182
Cell. 2022 Mar 3;185(5):872-880.e3
pubmed: 35123650
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
mBio. 2022 Apr 26;13(2):e0379821
pubmed: 35297676
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Science. 2020 Nov 20;370(6519):950-957
pubmed: 32972994
Cell. 2022 Jun 9;185(12):2116-2131.e18
pubmed: 35662412
Immunol Rev. 2022 Sep;310(1):6-26
pubmed: 35661178
J Exp Med. 2022 Dec 5;219(12):
pubmed: 36149398
Sci Transl Med. 2021 Jan 27;13(578):
pubmed: 33397677
Lancet Infect Dis. 2023 Jan;23(1):30-32
pubmed: 36495917
N Engl J Med. 2023 Feb 23;388(8):764-766
pubmed: 36734847
Cell Rep. 2022 Feb 15;38(7):110368
pubmed: 35123652
Sci Adv. 2021 May 28;7(22):
pubmed: 33888467
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Nature. 2019 Feb;566(7744):393-397
pubmed: 30664748
Nat Biotechnol. 1997 Sep;15(9):871-5
pubmed: 9306402
Cell Host Microbe. 2022 Jun 8;30(6):880-886.e4
pubmed: 35436444
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Cold Spring Harb Perspect Med. 2021 May 3;11(5):
pubmed: 31964645
Bioinformatics. 2021 May 5;37(5):734-735
pubmed: 32805021
Immunity. 2022 Sep 13;55(9):1725-1731.e4
pubmed: 35973428
Sci Immunol. 2022 Jul 29;7(73):eabq3511
pubmed: 35549299
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
N Engl J Med. 2023 Feb 16;388(7):662-664
pubmed: 36652339
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
Lancet Respir Med. 2021 Sep;9(9):999-1009
pubmed: 34224675
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
Nature. 2022 Jul;607(7917):128-134
pubmed: 35447027
Cell. 2022 May 26;185(11):1875-1887.e8
pubmed: 35523182